Cost-effectiveness of pharmaceutical smoking cessation intervention in China primary cancer prevention
10.3760/cma.j.cn112152-20231024-00229
- VernacularTitle:药物戒烟在中国恶性肿瘤一级预防中的卫生经济学评价
- Author:
Peiyuan SUN
1
;
Yuting XIE
;
Ranran QIE
;
Huang HUANG
;
Zhuolun HU
;
Mengyao WU
;
Qi YAN
;
Cairong ZHU
;
Jufang SHI
;
Kaiyong ZOU
;
Yawei ZHANG
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院预防控制部，北京 100021
- Keywords:
Tumor;
Smoking cessation;
Varenicline;
Cancer primary prevention;
Markov model;
Pharmacoeconomics;
Cost-effectiveness
- From:
Chinese Journal of Oncology
2024;46(1):66-75
- CountryChina
- Language:Chinese
-
Abstract:
Objectives:To evaluate the cost-effectiveness of typical pharmaceutical smoking cessation intervention strategies in China in the context of primary cancer prevention.Methods:Markov cohort simulation models were established to simulate the burden of 12 smoking caused cancer, including lung cancer, oral cancer, nasopharyngeal cancer, laryngeal cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, kidney cancer, bladder cancer, cervical cancer, and acute myeloid leukemia. Taking incremental cost effectiveness ratio (ICER) as the main indicator, the model sets one year as the cycling period for 50 periods and simulates the cohort of 10 000 thirty-five-year-old current smokers with various smoking cessation strategies. To ensure the robustness of conclusion, univariate sensitivity analysis, probability sensitivity analysis, and age-group sensitivity analysis were conducted.Results:The results showed that varenicline intervention was the most cost-effective intervention. Compared to the next most effective option, incremental cost of each additional quality-adjusted life year is 11 140.28 yuan, which is below the threshold of willingness to pay (1 year GDP per capita). The value of ICER increased as the increasing age group of adopting intervention, but neither exceeded the threshold of willingness to pay. One-way sensitivity analysis showed that the value of discount rate, the hazard ratio and cost of intervention strategy had a greater impact on the result of ICER.Conclusion:In China, the use of varenicline to quit smoking is highly cost effective in the context of cancer primary prevention, especially for younger smokers.
